|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Polysaccharides from Nostoc commune Vaucher activate macrophages via NF-κB and AKT/JNK1/2 pathways to suppress colorectal cancer growth in vivo.
|
31259992 |
2019 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Large tumor suppressor kinase 2 overexpression attenuates 5-FU-resistance in colorectal cancer via activating the JNK-MIEF1-mitochondrial division pathway.
|
31011291 |
2019 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, it has been shown that BEX2 promotes cell proliferation through the JNK/c-Jun pathway and regulates JNK/c-Jun phosphorylation in colorectal cancer.
|
30779920 |
2019 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study reveals that BEX2 promotes colorectal cancer cell proliferation via the JNK/c-Jun pathway, suggesting BEX2 as a potential candidate target for the treatment of CRC.
|
28367093 |
2017 |
|
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We found that NIBP, p-p65, p-ERK1/2, and p-JNK1/2 expression was higher in late stages of CRC compared to early stages or adenomas.
|
28125661 |
2017 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ki67 was inversely expressed, showing increased proliferation early in UC-CRC and CRC carcinogenesis. p-JNK1-3 was increased in AUC and QUC.
|
28383667 |
2017 |
|
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
TLE4 promotes colorectal cancer progression through activation of JNK/c-Jun signaling pathway.
|
26701208 |
2016 |
|
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
ROR2 knockdown in the CRC cell line HCT116 significantly decreased expression of the β-catenin independent Wnt targets genes JNK and NFATC1, increased cellular proliferation and migration but decreased invasion.
|
27440078 |
2016 |
|
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The development of colorectal cancer (CRC) is strongly correlated with the aberrant activation of multiple intracellular signaling transduction cascades including STAT3, ERK, JNK and p38 pathways which usually function redundantly.
|
23900560 |
2013 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Of note, lentiviral‑mediated continuous JARID1B depletion resulted in the loss of epithelial differentiation and suppressed CRC cell growth, which was associated with the induction of phosphorylation by the c‑Jun N‑terminal kinase (Jnk/Sapk) and senescence‑associated β‑galactosidase activity.
|
23354547 |
2013 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among these identified TFs, we obtained a novel six-node module consisting of ATF2-P53-JNK1-ELK1-EPHB2-HIF1A, from which the novel JNK1-ELK1 association could potentially be a significant marker for CRC.
|
22852817 |
2012 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, UA was also found to induce the expression of DRs, down-regulate cell survival proteins, and activate JNK in orthotopically implanted human colorectal cancer in a nude mouse model.
|
21156789 |
2011 |
|
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
(-)-Epigallocatechin-3-gallate promotes pro-matrix metalloproteinase-7 production via activation of the JNK1/2 pathway in HT-29 human colorectal cancer cells.
|
15860507 |
2005 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This implies that the constitutive activation of Akt and the p38, JNK of MAPK pathways in microcystin-transformed cells may be the mechanism by which this important external factor acts in the carcinogenesis of CRC.
|
15774489 |
2005 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings demonstrate that the constitutive activation of ERK1/2, JNK1 and p38 is not a feature of colorectal cancers.
|
10769637 |
2000 |